Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5449]

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine...

Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma ( Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China )

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Prognostic value of HER2-low status in breast cancer: A systematic review and...

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )

Extended lymph node removal does not benefit patients with clinically localised...

Dr Seth Lerner - Baylor College of Medicine, Houston, USA

Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer ( Dr Seth Lerner - Baylor College of Medicine, Houston, USA )

Dostarlimab chemo combination for primary advanced or recurrent endometrial...

Prof Matthew Powell - Washington University School of Medicine, Missouri, USA

Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer ( Prof Matthew Powell - Washington University School of Medicine, Missouri, USA )

2L triple metronomic chemo shows more efficacy in comparison to systemic...

Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital...

2L triple metronomic chemo shows more efficacy in comparison to systemic therapy for head and neck cancer ( Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital, Ahmedabad, India )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Ciltacabtagene autoleucel greatly reduces risk of disease progression in...

Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA

$Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM ( Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA )$

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Head and neck highlights

Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA

ASCO 2023: Head and neck highlights ( Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA )

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to...

Dr Brian Van Tine - Washington University in St Louis, St Louis, USA

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma ( Dr Brian Van Tine - Washington University in St Louis, St Louis, USA )

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment ( Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA )

More from ecancer